Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Allergan | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Allergan

Specialty pharma sales up 14% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Allergan

3Q Revenues:  $1.8 billion (+17%)

3Q Earnings: $312.5 million (+4%)

YTD Revenues: $5.3 billion (+15%)

YTD Earnings: $989.7 million (+47%)

Comments: Specialty pharmaceutical sales increased 14% to $1.5 billion in the quarter. Eye Care Pharmaceutical sales were $818.8 million in the quarter, up 14%. Botox/Neuromodulators sales were $560.1 million, up 15%. Total core medical device sales increased 30% to $258.9 million. Regarding the unsolicited proposal from Valeant, on September 15 Allergan reached an agreement with Valeant under which Allergan agreed to hold a Special Meeting of Stockholders. At press time, Valeant was willing to raise its offer for Allergan, to which Allergan replied it would consider a new formal offer from Valeant if one were presented, but that it believed the offers made to date had been inadequate.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters